Aeon Biopharma Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Aeon Biopharma Inc 's ROA in the second quarter of 2026?
Aeon Biopharma Inc recorded a cumulative net loss of $-55 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -757.76%.

However, within the Healthcare sector 918 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4643, from total ROA ranking in the first quarter of 2026 at 5313.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-49.32 %	-37.46 %	96.81 %	140.67 %	103.38 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-55	-60	-39	0	-293
Return On Assets (TTM)	-757.76 %	-695.19 %	-394.64 %	-0.03 %	-3674.46 %
AEON's Total Ranking	# 4643	# 5313	# 2563	# 4915	# 4965
Total Assets (TTM) in million	6	9	6	9	12
Seq. Total Assets Change	-31.52 %	55.22 %	-36.34 %	-25.11 %	-15.49 %
Seq. Net Income Change	-	-	-	-	-

AEON's 5 Years Annual ROA >> Back to AEON Management Effectiveness >> Compare AEON ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 440
Sector	# 919
Overall	# 4598

Return On Assets Statistics
High	Average	Low
478.83 %	-1018.33 %	-6272.88 %
(Jun 30 2024)		(Dec 31 2024)

News about Aeon Biopharma inc Return on Assets ROA

AEON Biopharmas Focus Realigns Towards Biosimilar Pathway for ABP-450 A Shift in Strategy

In recent news, AEON Biopharma, a prominent pharmaceutical company, announced a strategic reprioritization to pursue a biosimilar pathway for ABP-450. This shift in focus has come after the preliminary results of AEON Biopharma s Phase 2 trial for chronic migraine treatment failed to show significant improvement over a placebo. At the same time, AEON Biopharma s shares have been outperforming the market, indicating investor confidence in the company s new direction.AEON Biopharma s Phase 2 Trial for Chronic Migraine Treatment:Despite hopes for a breakthrough in the treatment of chronic migraines, AEON Biopharma s Phase 2 trial results fell short of expectations. The trial, which evaluated the efficacy of a potential migraine treatment, revealed no significant improvement when compared to a placebo. Although reductions in monthly migraine days were anticipated, it is clear that further research and development are needed. This setback has prompted AEON Biopharma to explore alternative avenues to ensure future success.

AEON Biopharma Implements Resource Reprioritization Plan to Ensure Stability and Fuel Future Growth

In a strategic move aimed at optimizing resources and reducing costs, AEON Biopharma recently announced a reprioritization plan. The company expects its current cash and cash equivalents to be adequate to sustain corporate operations until the fourth quarter of 2024. Meanwhile, AEON Biopharma is actively evaluating options for funding the future advancement of its late-stage clinical pipeline.
This announcement comes in the wake of AEON Biopharma s impressive financial performance in the fourth quarter of 2023. The company s return on assets (ROA) reached an impressive 39.32%, surpassing its average ROA of 7.74%. This improvement in ROA can be attributed to significant growth in net income.

Financial Statements
Aeon Biopharma Inc 's Assets	$ 6 million	AEON's Balance sheet
Aeon Biopharma Inc 's Income	$ -1 million	Quarterly AEON's Income Statement
AEON's Income by Division		See AEON's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	FY
Y / Y Total Assets Change	96.81 %	-58.73 %	-97.55 %	0.81 %	-
Total Assets in million	6	3	7	279	277
Y / Y Net Income Change	-	558.87 %	-22.26 %	-	-
Net Income in million	-39	42	6	8	0
Annual Return On Assets	-705.43 %	1486.9 %	93.14 %	2.94 %	-

AEON's 5 Years Annual ROA >> Back to AEON Management Effectiveness >> Compare AEON ROA to its Competitors

More Return On Assets Ratios
AEON's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AEON's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AEON's Competitors
Subscribers only: Roa for Aeon Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for AEON's Customers

You may also want to know
AEON's Roi	AEON's Inventory Turnover Ratio	AEON's Growth Rates	AEON's Dividend Comparisons
	AEON's Profitability Ratios	AEON's Asset Turnover Ratio	AEON's Dividend Growth
AEON's Roe	AEON's Valuation Ratios	AEON's Financial Strength Ratios	AEON's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T11:27:53+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.